Join the Xgeva group to help and get support from people like you.
Xgeva News
Denosumab Linked to Severe Hypocalcemia in Dialysis-Dependent Seniors
THURSDAY, Jan. 25, 2024 – For female dialysis-dependent patients aged 65 years or older treated for osteoporosis, denosumab is associated with an increased incidence of severe or very severe...
Industry Payments to Doctors Tied to Nonrecommended, Low-Value Drug Use
FRIDAY, Oct. 27, 2023 – Industry payments to physicians are associated with nonrecommended and low-value drugs, according to a study published online Oct. 25 in The BMJ. Aaron P. Mitchell, M.D.,...
FDA Approves Xgeva (denosumab) for the Prevention of Skeletal-Related Events in Patients with Multiple Myeloma
THOUSAND OAKS, Calif., Jan. 5, 2018 /PRNewswire/ – Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application...
FDA Approves Xgeva (denosumab) for Hypercalcemia of Malignancy Refractory to Bisphosphonate Therapy
THOUSAND OAKS, Calif., Dec. 8, 2014 /PRNewswire/ – Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved a new indication for Xgeva (denosumab) for the...
FDA Approves Xgeva to Treat Giant Cell Tumor of the Bone
June 13, 2013 – The U.S. Food and Drug Administration today expanded the approved use of Xgeva (denosumab) to treat adults and some adolescents with giant cell tumor of the bone (GCTB), a rare and...
Ask a question
To post your own question to this support group, sign in or create an account.